Web Content Display



Impact Clinical and Epidemiological characteristics


I-ADNI is a cross sectional study and consists of 262 patients with subjective memory impairment, mild cognitive impairment, Alzheimer's dementia, and frontotemporal dementia enrolled in 7 Italian centers. Few cognitively healthy elderly controls were also included. This study has provided standardization of MRI acquisition and imaging marker collection across different Italian clinical units and equipment. This is a mandatory step to the implementation of imaging biomarkers in clinical routine for early and differential diagnosis. MRI site qualification and MP-RAGE quality assessment was applied following the NA-ADNI procedures.
ADHD-200 Attention Deficit Hyperactivity Disorder affects at least 5-10% of school-age, with annual direct costs exceeding $36 billion/year. The ADHD-200 Sample is a grassroots initiative, dedicated to accelerating the scientific community's understanding of the neural basis of ADHD through the implementation of open data-sharing and discovery-based science. Towards this goal, ADHD OFFERS the unrestricted public release of 776 resting-state fMRI and anatomical datasets aggregated across 8 independent imaging sites, 491 of which were obtained from typically developing individuals and 285 in children and adolescents with ADHD (ages: 7-21 years old). Accompanying phenotypic information includes: diagnostic status, dimensional ADHD symptom measures, age, sex, intelligence quotient (IQ) and lifetime medication status.
OASIS Aims to facilitate future discoveries in basic and clinical neuroscience OASIS (Open Access Series of Imaging Studies) consists of (I) a cross-sectional collection of 416 subjects aged 18 to 96. 100 of the included subjects over the age of 60 have been clinically diagnosed with very mild to moderate Alzheimer's disease (AD). (II) A longitudinal collection of 150 subjects aged 60 to 96. Each subject was scanned on two or more visits, separated by at least one year for a total of 373 imaging sessions. For each subject, 3 or 4 individual T1-weighted MRI scans obtained in single scan sessions are included. The subjects are all right-handed and include both men and women. 72 subjects were non demented, 64 were demented, including 51 individuals with mild to moderate Alzheimer's disease
ADNI-1 ADNI-1 supports research in the discovery and development of treatments that slow or stop the progression of AD. Its goal is to determine the characteristics of AD as the pathology evolves from normal aging to mild symptoms, to MCI, to dementia. 200 healthy older persons, 400 patients with mild cognitive impairment (MCI) and 200 with Alzheimer's disease. Structural MR serial scans at 1.5T every 6 months for 4 years in 100% and at 3T in 50%, FDG PET every 12 months in 50%, serial CSF markers in over 60%, genome wide scan in 100%, and amyloid imaging with 11C PIB in a restricted group, All data are de-identified.
ADNI-GO This dataset will better explore earlier stages of MCI; to study novel imaging markers Expands ADNI-1 (already ported in neuGRID) by 200 additional patients with early MCI; all patients undergo structural MRI scans at 3 T at four time points, amyloid imaging with a fluorinated ligand, resting‐state fMRI in Philips scanners, diffusion MRI in GE scanners, and CSF studies
ADNI-2 This dataset will extend the observation window of the MCI stage to earlier and later stages ADNI-2 will study and follow 500 additional individuals
H2H Comparison Study Aim of this study was to assess the reliability of two widely used pipelines, CIVET and FREESURFER, with a view of a possible clinical exploitation of cortical thickenss as AD marker (Redolfi et al., 2015). Images from 185 ADNI1 cases (69 elderly controls (CTR), 37 stable MCI (sMCI), 27 progressive MCI (pMCI), and 52 Alzheimer (AD) patients, scanned at BSL, M12, and M24, were processed with CIVET v1.1.9 and FREESURFER v5.3.0 allowing a head to head (H2H) comparison at vertex level.
1000 FUNCTIONAL CONNECTOMES PROJECT This dataset will equip researchers with a means of exploring and refining rest-fMRI approaches Unrestricted public release of 1200 ˜resting state' functional MRI 4D-Images independently collected at 33 sites. All images form the broader imaging community complete access to a large-scale functional imaging dataset. Age, sex and imaging centre information are provided for each of the images. In accordance with HIPAA guidelines, all images are anonymous, with no protected health information included.
PHARMACOG - MCI PATIENTS - PHARMACOG (alias E-ADNI) marks the start of the most ambitious European project for tackling bottlenecks in Alzheimer's disease research and drug discovery. PharmaCog, is short for "Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in early clinical development". It is a partnership of 32 academic and industry actors from 7 countries, co-ordinated by GlaxoSmithKline R&D and the Université de la Méditerranée, started its activities on January 1, 2010 thanks to significant funding (EUR 20.2 million) from the Innovative Medicines Initiative. 147 MCI patients are studied along 7 time points (i.e.: BSL, T06, T12, T18, T24, T30 and T36).
PHARMACOG-DTI-Reproducibility This multi-site 3T diffusion MRI study (10 sites) quantifies the across-session test-retest reproducibility errors in healthy elderly volunteers of scalar DTI metrics (fractional anisotropy, mean/radial/axial diffusivity). The data is analyzed using both full brain TBSS and atlas-based ROIs on the white matter skeleton. The study demonstrates reproducibility errors that are not site dependent and consistent with those of other studies using lower number of sites or hand-drawn ROI analyses. (Jovicich et al., 2014) 50 healthy Caucasian subjects (50-80 years) were scanned in two sessions at least a week apart in 10 clinical 3T scanners distributed in Europe (5 subjects per site). Each acquisition session has one diffusion acquisition 2x2x2 mm3, b=700 s/mm2, 5 b0 and 30 diffusion weighted volumes. Scanner vendors were Siemens (Allegra, TrioTim, Verio, Skyra, MRBiograph), Philips (Achieva) and GE (Signa HDxt). The 100 raw diffusion datasets are available. Images are anonymous.
PHARMACOG-Morphometry-Reproducibility This multi-site 3T morphometry study (8 MRI sites) evaluates the across-session test-retest reproducibility errors in healthy elderly volunteers analyzed using two automated brain segmentation methods: cross-sectional and longitudinal Freesurfer segmentation of cortical thickness and subcortical/ventricular volumes.  The study demonstrates consistent and significant improvement of the reliability with the longitudinal analysis

(Jovicich et al., 2013).

40 healthy Caucasian subjects (50-80 years) were scanned in two sessions at least a week apart in 8 clinical 3T scanners distributed in Europe (5 subjects per site). Each acquisition session has two 3D T1-weighted images (1x1x1 mm3). Scanner vendors were Siemens (Allegra, TrioTim, Verio, Skyra), Philips (Achieva) and GE (Signa HDxt). Two volumes were not acquired giving a total of 158 brain volumes available. Images are anonymous.

PHARMACOG-resting-state-fMRI-Reproducibility This multi-site 3T resting state fMRI study (13 sites) quantifies the across-session test-retest reproducibility errors in healthy elderly volunteers of the intrinsic connectivity in the default mode network. The study demonstrates that ICA gives better reproducibility than seed-based analysis, and consistent across the consortium (Jovicich, et al., 2015) 65 healthy Caucasian subjects (50-80 years) were scanned in two sessions at least a week apart in 13 clinical 3T scanners distributed in Europe (5 subjects per site). Each acquisition session includes the acquisition of two 3D MPRAGE structural images, and one resting state BOLD fMRI acquisition (3x3x3 mm3, TR=2.7 s, TE=30ms, 200 volumes). Scanner vendors were Siemens (Allegra, TrioTim, Verio, Skyra, MRBiograph), Philips (Achieva) and GE (Signa HDxt, Discovery MR750). The anonimized nifti raw datasets for the 130 acquisition sessions are available
EDSD Assessment of disability in older people The EDSD data includes 471 Diffusion Tensor Imaging (DTI) and 471 structural MRI scans (MPRAGE) from patients with Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI) and Healthy Elderly Subjects. The EDSD is a cross-sectional multicenter study.
VITA Vienna Transdanube Aging Study VITA is a population based cohort-study of all 75-years old inhabitants of a geographically defined area of Vienna. VITA is composed by 606 subjects followed longitudinally for 4 years. Recruitment took place between May 2000 and October 2002. The primary focus of the VITA work group was to establish a prospective age cohort for evaluation of prognostic criteria for the development of AD.
WMH-AD WMH-AD WMH-AD (White matter hyperintensities in Alzheimer's disease):
Alzheimer's disease (AD) is the most common forms of dementia in older individuals. The pathogenesis has traditionally been thought as a neurodegenerative process with the accumulation of amyloid-β (Aβ) and neurofibrillary tangles in various regions of the cortex. In recent years, there is an increased interest in white matter changes and, at least 50% of patients with AD, have been documented with this pathological change. White matter provides anatomic connections among brain regions and severe WMHs burden may contribute to cognitive impairment. Therefore, collecting many imaging scans this study hopes to get a better understanding about the WMH in AD.
WMH-AD is composed by 92 subjects (30 men and 62 women) followed cross-sectionally. The patients underwent to the following imaging scans: T13D, FLAIR, and DTI (61 gradient directions) at 3.0 Tesla.
MIRIAD Multiple institution effort for automated analyses of PD and T2-weighted MR from a longitudinal study of depression in late life A multiple institution study of structural MRI, including raw PD and T2 MRIs and derived measures of white matter changes, basal ganglia and other regions. Demographic and extensive clinical assessment data is available for each case.
fBIRN PHASE I The purpose of this study was to provide an excellent dataset with which to assess test-retest and between-site reliability of fMRI and to provide a rich data set to test tool and methods to allow for calibration of between site differences in FMRI results. This dataset includes five healthy subjects imaged twice at each of ten FBIRN MRI scanners on successive days. Functional and structural imaging, behavioral, and demographic data are available from 100 scanning sessions on these subjects.
fBIRN PHASE II A multi-centric effort for the characterization of schizophrenia disease The FBIRN multi-site dataset of subjects with schizophrenia and controls includes functional MRI images, behavioral data, demographic, and clinical assessments on 253 subjects from around the US. Subjects were recruited locally, evaluated with a standardized clinical assessment battery, and scanned twice at each of the 9 participating FBIRN sites. A standard FBIRN protocol was used for image acquisition with controlled variation at different sites and included a sensorimotor task (SM), an Auditory Oddball task (AO), a Serial Item Recognition Paradigm (SIRP), and a breath-hold task (BH).
NUSDAST NU Schizophrenia Data and Software Tool Federation using BIRN Infrastructure NUSDAST offers high-resolution magnetic resonance (MR) datasets from large cohorts of subjects using the same MR scanner platform and sequences. In addition, this project makes available MR images, demographic, clinical, neurocognitive and genotype data from 139 subjects with schizophrenia and 136 control subjects matched for age and gender.

Magnetic Resonance Imaging in MS MAGNIMS is a European network of academics that share a common interest in the study of multiple sclerosis using magnetic resonance imaging technique. Such a group has collaborated since 1990 and has collectively made a major contribution to defining the role of MRI in diagnosis and monitoring treatments in MS.
ARWIBO Identification of surrogate biomarkers sensitive to disease stage. This dataset is very useful to make comparison between the CTR subjects and MCI as well as patients in the AD stage. ARWIBO is a cross-sectional dataset including data from more than 2700 patients enrolled in Brescia and nearby areas. The database contains data of healthy elderly Controls (CTR), individual with Mild Cognitive Impairment (MCI), and patients with Alzheimer's disease. Images are both structural images weighted in T1 and T2 (at 1.0T or 1.5T) as well as PET scans. All data are de-identified.
ABIDE To facilitate the advance in the neuroimaging research: generating and testing new hypotheses related to Autism. The Autism Brain Imaging Data Exchange (ABIDE) provides resting state functional magnetic resonance imaging (R-fMRI) datasets from 539 individuals with Autism Spectrum Disorders (ASD) and 573 typical controls for the purpose of data sharing in the broader scientific community. This initiative involved 16 international sites, sharing 20 samples yielding 1112 datasets composed of both MRI data and an array of phenotypic information
INDI This study can be used to objective measure the brain functions capable of detecting and monitoring the pathophysiological processes underlying neurological and psychiatric illness The INDI-DWI datasets (i.e. : NKI, Beijing Enhance, Beijing short TR study) is composed by 415 subjects. The main diagnoses are: community sample individuals with ages of 4 and 85 years). Imaging modalities are represented by T13D, R-fMRI and DWI.
COBRE A characterization study of the brain in schizophrenia This dataset is composed by anatomical and functional MR data from 72 patients with Schizophrenia and 75 healthy controls (ages ranging from 18 to 65 in each group).